PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: inGenious Targeting Laboratory, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

inGenious Targeting Laboratory, Inc. Announces New Headqueaters - inGenious Targeting Laboratory's larger, state-of-the-art headquarters will provide provide iTL with new opportunities as iTL continues to define itself as a leader in the custom mouse model industry - Genetargeting.com
inGenious Targeting Laboratory, Inc. Announces New Headqueaters

 

NewswireToday - /newswire/ - Ronkonkoma, NY, United States, 2012/01/31 - inGenious Targeting Laboratory's larger, state-of-the-art headquarters will provide provide iTL with new opportunities as iTL continues to define itself as a leader in the custom mouse model industry - Genetargeting.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

inGenious Targeting Laboratory (iTL), a leader in the industry of genetically modified mice, announces the relocation of their world headquarters to a new facility in Ronkonkoma, NY. The move, in response to an expanding staff and increasing technical demands, will allow iTL to provide its employees with additional space and tools to address their client’s evolving research needs.
“The new laboratory will provide iTL with the room to accommodate an increasing client base. It will also give us the capacity to broaden the scope of the technology used to address new, and potential challenges in the strategy design and execution of customized gene targeted mouse models,” said iTL’s President and COO Paul Sheiffele. “We are delighted to move into this new space, and are excited to be a part of the growing life science community in the area.”

The new headquarters, located at 2200 Smithtown Ave, Ronkonkoma, NY is surrounded by world-class research facilities such as, Stony Brook University, Cold Spring Harbor and Brookhaven National Laboratory; institutions which iTL has shared long-standing relationships with.

About inGenious Targeting Laboratory (iTL)

inGenious Targeting Laboratory, Inc. (genetargeting.com) was founded in 1998, and is a global provider of gene targeting and custom mouse model production and services. iTL has delivered over eleven hundred successful custom mouse models to investigators worldwide. iTL is dedicated exclusively to the generation of customized gene targeted mouse models for the research community including researchers in academic and medical institutes, government research centers, and pharmaceutical and biotechnology companies. Clients retain full intellectual property rights to their projects. A full range of project capabilities are available including conventional knockout, conditional knockout, knockin, reporter genes, knockin human/murine cDNAs, targeted transgenic models, as well as novel approaches for custom models. Full-service customer projects are initiated immediately upon completion of design parameters and progress to completion on-site.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: inGenious Targeting Laboratory, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


inGenious Targeting Laboratory, Inc. Announces New Headqueaters

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tegan Ryan - GeneTargeting.com 
631-681-5653 marketing[.]genetargeting.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any inGenious Targeting Laboratory, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From inGenious Targeting Laboratory, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)